Roivant Sciences Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ROIV research report →
Companyroivant.com
Roivant Sciences Ltd. , a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- CEO
- Matthew Gline
- IPO
- 2020
- Employees
- 908
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $22.74B
- P/E
- -73.66
- P/S
- 2757.38
- P/B
- 4.17
- EV/EBITDA
- -67.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.44%
- Op Margin
- -6235.69%
- Net Margin
- -3629.19%
- ROE
- -6.56%
- ROIC
- -12.00%
Growth & Income
- Revenue
- $8.26M · -71.57%
- Net Income
- $-299,771,000 · -74.30%
- EPS
- $-0.43 · -79.17%
- Op Income
- $-515,068,000
- FCF YoY
- 10.13%
Performance & Tape
- 52W High
- $32.16
- 52W Low
- $10.59
- 50D MA
- $28.34
- 200D MA
- $21.66
- Beta
- 1.14
- Avg Volume
- 6.02M
Get TickerSpark's AI analysis on ROIV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | Venker Eric | other | 200,000 |
| Apr 20, 26 | Venker Eric | other | 200,000 |
| Apr 20, 26 | Venker Eric | sell | 200,000 |
| Apr 20, 26 | Pulik Richard | other | 60,644 |
| Apr 20, 26 | Pulik Richard | other | 84,026 |
| Apr 20, 26 | Humes Jennifer | other | 29,173 |
| Apr 20, 26 | Humes Jennifer | other | 27,157 |
| Apr 17, 26 | Oren Ilan | other | 896 |
| Apr 17, 26 | Oren Ilan | other | 95 |
| Apr 17, 26 | Epperly Melissa B, | other | 670 |
Our ROIV Coverage
View all →
Roivant Sciences (ROIV): Cash-Rich Biotech Catalysts Ahead
Roivant pairs a $4.3B cash base with multiple late-stage catalysts, led by brepocitinib’s near-term launch path and several 2H 2026 readouts. The stock looks like a selective Buy, but execution risk remains high given heavy cash burn and limited current revenue.
Roivant Sciences Ltd. (ROIV) climbs above 52-week high
Roivant Sciences Ltd. (ROIV) climbs after hours following its May 20 earnings and business update. The biotech’s rally is tied to encouraging pipeline progress, strong cash reserves, and analyst optimism, pushing shares above their prior 52-week high as investors reassess the company’s platform value.
Want a deeper read on ROIV?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.